Last reviewed · How we verify

NCT04798898: ISCOLIM

Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation

Recruiting now NA Last updated 5 December 2024
What this trial tests

NA trial testing RFA (radiofrequency ablation) in Liver Metastasis Colon Cancer in 200 participants. Currently enrolling.

Timeline
14 November 2022
Primary endpoint
1 June 2025
1 December 2026

Quick facts

Lead sponsorUniversity of Aarhus
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment200
Start date14 November 2022
Primary completion1 June 2025
Estimated completion1 December 2026
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

University of Aarhus

Who can join

Adults 18 to 99, any sex, with Liver Metastasis Colon Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Metastasis Colon Cancer

Currently open trials in the same condition.

Other University of Aarhus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04798898.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing